SAFETY AND ACTIVITY OF VARLILUMAB, A NOVEL AND FIRST-IN-CLASS AGONIST ANTI-CD27 ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS

Wednesday, July 26, 2017